Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.57 |
| ▸ | RXRA | P19793 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8155275 | 0.91 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17819199 | 0.90 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17819202 | 0.90 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17848221 | 0.87 | CA12 (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17848264 | 0.87 | CA12 (0.56) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17848206 | 0.85 | CA12 (0.54) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17821316 | 0.85 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17821315 | 0.85 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17848266 | 0.85 | CA12 (0.54) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17821314 | 0.84 | PPARG (0.56) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680073-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | ADT PHARMACEUTICALS, LLC (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680073-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | ADT PHARMACEUTICALS, LLC (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220048931-A1 | ANTICANCER INDENES, INDANES, AZAINDENES, AZAINDANES, PHARMACEUTICAL COMPOSITIONS AND USES | ADT PHARMACEUTICALS, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11186596-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | ADT PHARMACEUTICALS, LLC (US) | 2021-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048931-A1 | ANTICANCER INDENES, INDANES, AZAINDENES, AZAINDANES, PHARMACEUTICAL COMPOSITIONS AND USES | CDKN1A, CCNA1, CCNA2 | PPARG 3173/4885RXRA 725/4885CYP1A2 10/4885 |
| US-11186596-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | CCNA2, CDKN1A, CCNA1 | PPARG 3107/4885RXRA 724/4885CYP1A2 6/4885 |
| US-11680073-B2 | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses | CDKN1A, CCNA1, CCNA2 | PPARG 3173/4885RXRA 725/4885CYP1A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.